May 10, 2018
Data shed light on patents' attitudes towards kids' sunblock and new findings emerge on melanoma risks. FDA accepts BLA for cemiplimab for advanced SCC and approves Novartis' Tafinlar in combination with Mekinist for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations. Data highlight clinical experience with Epiduo Forte Gel. Encore Dermatology launches Impoyz Cream.